Publication Name	World Journal of Diabetes
Manuscript ID	4205
Country	Greece

Received	2013-06-20 08:41
Peer-Review Started	2013-06-20 13:52
To Make the First Decision	2013-07-05 18:21
Return for Revision	2013-07-15 22:48
Revised	2013-07-25 03:18
Second Decision	2013-08-16 19:51
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2013-08-17 00:42
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2013-09-22 10:32
Publish the Manuscript Online	2013-10-16 11:30

ISSN	1948-9358 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Endocrinology & Metabolism
Manuscript Type	Review
Article Title	Effects of glucagon-like peptide-1 receptor agonists on renal function
Manuscript Source	Invited Manuscript
All Author List	Theodosios D Filippatos and Moses S Elisaf
Funding Agency and Grant Number
Corresponding Author	Moses S Elisaf MD, FRSH, FASA, FISA, Professor, Department of Internal Medicine, School of Medicine, University of Ioannina, Staurou Niarchou Avenue, 45110 Ioannina, Greece. egepi@cc.uoi.gr
Key Words	Glucagon-like peptide 1; Glucagon-like peptide 1 receptor agonists; Exenatide; Liraglutide; Kidney; Renal impairment; Diabetic nephropathy; Electrolytes
Core Tip	Glucagon-like peptide 1 (GLP-1) receptor agonists improve glycemic control in patients with type 2 diabetes mellitus. A number of case reports show an association of GLP-1 receptor agonists, mainly exenatide, with the development of acute kidney injury. Exenatide is eliminated by renal mechanisms, but liraglutide is not eliminated by renal or hepatic mechanisms. GLP-1 receptor agonists exert protective role in animal models of diabetic nephropathy. The effects of these drugs may represent new ways to improve or even prevent diabetic nephropathy, but their exact mechanism of action need to be elucidated.
Publish Date	2013-10-16 11:30
Citation	Filippatos TD, Elisaf MS. Effects of glucagon-like peptide-1 receptor agonists on renal function. World J Diabetes 2013; 4(5): 190-201
URL	http://www.wjgnet.com/1948-9358/full/v4/i5/190.htm
DOI	http://dx.doi.org/10.4239/wjd.v4.i5.190

Full Article (PDF)	WJD-4-190.pdf
Manuscript File	4205-Review.doc
Answering Reviewers	4205-Answering reviewers.pdf
Copyright License Agreement	4205-Answering reviewers.pdf
Peer-review Report	4205-Peer review(s).pdf
Scientific Editor Work List	4205-Scientific editor work list.doc